HU229571B1 - Aqueous compositions containing moxifloxacin and common salt and process for its preparation - Google Patents
Aqueous compositions containing moxifloxacin and common salt and process for its preparation Download PDFInfo
- Publication number
- HU229571B1 HU229571B1 HU0203619A HUP0203619A HU229571B1 HU 229571 B1 HU229571 B1 HU 229571B1 HU 0203619 A HU0203619 A HU 0203619A HU P0203619 A HUP0203619 A HU P0203619A HU 229571 B1 HU229571 B1 HU 229571B1
- Authority
- HU
- Hungary
- Prior art keywords
- tea tea
- hydrochloride
- mixed
- preparation
- aqueous
- Prior art date
Links
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title claims description 49
- 239000000203 mixture Substances 0.000 title claims description 37
- 239000011780 sodium chloride Substances 0.000 title claims description 27
- 238000002360 preparation method Methods 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 5
- 235000002639 sodium chloride Nutrition 0.000 title description 26
- 229960003702 moxifloxacin Drugs 0.000 title description 10
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 title description 10
- 239000000243 solution Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 claims 1
- 230000003165 hydrotropic effect Effects 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 26
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 description 14
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 description 14
- 229910052742 iron Inorganic materials 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 241001122767 Theaceae Species 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- -1 kakir Chemical compound 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- BFTGQIQVUVTBJU-UHFFFAOYSA-N 5,6-dihydroimidazo[2,1-c][1,2,4]dithiazole-3-thione Chemical compound C1CN2C(=S)SSC2=N1 BFTGQIQVUVTBJU-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- XEGGRYVFLWGFHI-UHFFFAOYSA-N bendiocarb Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)O2 XEGGRYVFLWGFHI-UHFFFAOYSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960004385 danofloxacin Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- NRBJWZSFNGZBFQ-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 NRBJWZSFNGZBFQ-UHFFFAOYSA-N 0.000 description 1
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 235000021537 Beetroot Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 241000589483 Coleogyne Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 240000007001 Rumex acetosella Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 229960004055 ciprofloxacin lactate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008225 water for inhalation Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19937116A DE19937116A1 (de) | 1999-08-06 | 1999-08-06 | Moxifloxacin Kochsalzformulierung |
| PCT/EP2000/007098 WO2001010465A1 (de) | 1999-08-06 | 2000-07-25 | Moxifloxacin kochsalzformulierung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0203619A2 HUP0203619A2 (hu) | 2003-02-28 |
| HUP0203619A3 HUP0203619A3 (en) | 2003-12-29 |
| HU229571B1 true HU229571B1 (en) | 2014-02-28 |
Family
ID=7917417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203619A HU229571B1 (en) | 1999-08-06 | 2000-07-25 | Aqueous compositions containing moxifloxacin and common salt and process for its preparation |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6548079B1 (pt) |
| EP (1) | EP1206281B1 (pt) |
| JP (1) | JP5522877B2 (pt) |
| KR (1) | KR100735788B1 (pt) |
| CN (1) | CN1246039C (pt) |
| AR (1) | AR025001A1 (pt) |
| AT (1) | ATE270104T1 (pt) |
| AU (1) | AU771058B2 (pt) |
| BG (1) | BG65304B1 (pt) |
| BR (1) | BRPI0013010B8 (pt) |
| CA (1) | CA2378424C (pt) |
| CO (1) | CO5190677A1 (pt) |
| CU (1) | CU23367A3 (pt) |
| CZ (1) | CZ298768B6 (pt) |
| DE (2) | DE19937116A1 (pt) |
| DK (1) | DK1206281T3 (pt) |
| EE (1) | EE04771B1 (pt) |
| ES (1) | ES2223549T3 (pt) |
| GT (1) | GT200000123A (pt) |
| HK (1) | HK1049615B (pt) |
| HN (1) | HN2000000115A (pt) |
| HR (1) | HRP20020198B1 (pt) |
| HU (1) | HU229571B1 (pt) |
| IL (2) | IL147553A0 (pt) |
| MA (1) | MA25427A1 (pt) |
| MX (1) | MXPA02001254A (pt) |
| MY (1) | MY125356A (pt) |
| NO (1) | NO320743B1 (pt) |
| NZ (1) | NZ516969A (pt) |
| PE (1) | PE20010400A1 (pt) |
| PL (1) | PL198132B1 (pt) |
| PT (1) | PT1206281E (pt) |
| RU (1) | RU2260429C9 (pt) |
| SI (1) | SI1206281T1 (pt) |
| SK (1) | SK285650B6 (pt) |
| TW (1) | TWI238719B (pt) |
| UA (1) | UA72268C2 (pt) |
| UY (1) | UY26269A1 (pt) |
| WO (1) | WO2001010465A1 (pt) |
| ZA (1) | ZA200200215B (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19937116A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| DE10218328A1 (de) | 2002-03-05 | 2003-09-25 | Humboldt Uni Zu Berlin Medizin | Mittel zur präventiven Therapie nach akutem Schlaganfall |
| US20040197408A1 (en) * | 2002-12-30 | 2004-10-07 | Angiotech International Ag | Amino acids in micelle preparation |
| WO2006015545A1 (fr) * | 2004-08-11 | 2006-02-16 | Shenzhen Tys R & D Co., Ltd. | Capsule de gelatine de moxifloxacin et procede pour sa preparation |
| JO2752B1 (en) * | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO3270B1 (ar) * | 2005-06-28 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا |
| DE102006031175A1 (de) * | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur |
| US7537532B2 (en) * | 2007-05-16 | 2009-05-26 | Young Carl D | Handle for implement and method |
| CN101787022B (zh) * | 2009-10-09 | 2012-08-22 | 浙江医药股份有限公司新昌制药厂 | 一种喹啉羧酸盐酸盐一水合物晶型及其制备方法 |
| WO2011086577A2 (en) * | 2010-01-12 | 2011-07-21 | Msn Laboratories Limited | Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts |
| CN101836950A (zh) * | 2010-03-12 | 2010-09-22 | 陕西合成药业有限公司 | 一种盐酸莫西沙星葡萄糖注射液及其制备方法和用途 |
| CN103919779B (zh) * | 2010-09-10 | 2016-02-10 | 杭州民生药业有限公司 | 一种含有莫西沙星的药物组合物 |
| CN102100666B (zh) * | 2011-01-17 | 2012-07-18 | 南京新港医药有限公司 | 一种新的盐酸莫西沙星注射剂 |
| CN102093349B (zh) * | 2011-01-17 | 2012-03-07 | 南京新港医药有限公司 | 一种工业化生产盐酸莫西沙星的方法 |
| CN102688183B (zh) * | 2011-03-21 | 2016-04-06 | 重庆医药工业研究院有限责任公司 | 一种稳定的盐酸莫西沙星注射剂 |
| KR101435244B1 (ko) * | 2011-04-12 | 2014-08-29 | 씨제이헬스케어 주식회사 | 목시플록사신 수성 제형 및 이의 제조방법 |
| KR101327904B1 (ko) * | 2011-08-16 | 2013-11-13 | 대한약품공업 주식회사 | 목시플록사신 염산염의 주사제형 |
| RU2472507C1 (ru) * | 2012-02-01 | 2013-01-20 | Закрытое акционерное общество "Брынцалов-А" | Водный состав на основе моксифлоксацина для парентерального введения |
| CN102600093B (zh) * | 2012-04-11 | 2013-06-05 | 南京优科生物医药有限公司 | 一种莫西沙星片剂及其制备方法 |
| GR1008168B (el) | 2013-03-14 | 2014-04-08 | "Φαρματεν Α.Β.Ε.Ε.", | Παρεντερικο σκευασμα αντιβακτηριακου παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου |
| CN103191056B (zh) * | 2013-04-28 | 2014-10-22 | 南京海融医药科技有限公司 | 莫西沙星的口服液体制剂及其制备方法和应用 |
| WO2015093669A1 (ko) * | 2013-12-20 | 2015-06-25 | 씨제이헬스케어 주식회사 | 목시플록사신 수성 제형 및 이의 제조방법 |
| CN103976944A (zh) * | 2014-05-16 | 2014-08-13 | 成都青山利康药业有限公司 | 一种盐酸莫西沙星氯化钠注射液 |
| CN104771359A (zh) * | 2015-04-02 | 2015-07-15 | 南京正大天晴制药有限公司 | 一种稳定的盐酸莫西沙星注射液 |
| CN105640876B (zh) * | 2016-01-07 | 2019-04-12 | 天津红日药业股份有限公司 | 一种盐酸莫西沙星氯化钠注射液的制备工艺 |
| US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
| EP3578182A1 (en) * | 2018-06-05 | 2019-12-11 | Bayer Animal Health GmbH | Formulations containing triazinones and iron with a low amount of free iron ions |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| CN111388415A (zh) * | 2020-03-19 | 2020-07-10 | 石家庄四药有限公司 | 一种盐酸莫西沙星氯化钠注射液及其制备方法 |
| EP4238552A1 (en) | 2020-10-29 | 2023-09-06 | Taejoon Pharmaceutical Co., Ltd. | Ophthalmic composition |
| CN115944586A (zh) * | 2023-01-17 | 2023-04-11 | 江苏睿实生物科技有限公司 | 一种盐酸莫西沙星制剂的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3537761A1 (de) | 1985-10-24 | 1987-04-30 | Bayer Ag | Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure |
| JPH01258620A (ja) * | 1988-04-08 | 1989-10-16 | Dai Ichi Seiyaku Co Ltd | 耳疾患用局所製剤 |
| DE3906365A1 (de) | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
| CA2053926A1 (en) * | 1989-04-28 | 1990-10-29 | Genkichi Ohta | Anti-hiv agent |
| JP3153549B2 (ja) | 1989-12-29 | 2001-04-09 | アボツト・ラボラトリーズ | キノロンカルボン酸―金属イオン―酸錯体 |
| US5084276A (en) | 1990-01-05 | 1992-01-28 | Abbott Laboratories | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation |
| FR2681863B1 (fr) | 1991-09-27 | 1995-02-03 | Rhone Dpc Europ | Solution de sparfloxacine sa preparation et sel la constituant. |
| DE4306417A1 (de) * | 1993-03-02 | 1994-09-08 | Grace Gmbh | Vorrichtung und Verfahren zum Verbrennen oxidierbarer Bestandteile in einem zu reinigenden Trägergas |
| CA2152828A1 (en) * | 1993-03-16 | 1994-07-07 | Shin-Ichi Uesato | 8-methoxy-quinolonecarboxylic acid derivatives |
| KR960000223A (ko) | 1994-06-08 | 1996-01-25 | 김정순 | 신규한 피리돈 카르복실산 화합물을 함유한 수용액 및 이의 제조방법 |
| EP0868183B1 (en) | 1995-12-21 | 2002-01-30 | Pfizer Inc. | Injectable quinolone formulations |
| JPH1192375A (ja) * | 1997-09-25 | 1999-04-06 | Morinaga Milk Ind Co Ltd | ニューキノロン系抗菌剤の抗菌性を増強させる抗菌剤 |
| AR020661A1 (es) * | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento |
| HU229065B1 (en) * | 1998-11-10 | 2013-07-29 | Bayer Ip Gmbh | Pharmaceutical moxifloxacin compositions |
| DE19937115A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon |
| DE19937116A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
-
1999
- 1999-08-06 DE DE19937116A patent/DE19937116A1/de not_active Withdrawn
-
2000
- 2000-07-06 HN HN2000000115A patent/HN2000000115A/es unknown
- 2000-07-25 EE EEP200200060A patent/EE04771B1/xx unknown
- 2000-07-25 DE DE50006974T patent/DE50006974D1/de not_active Expired - Lifetime
- 2000-07-25 WO PCT/EP2000/007098 patent/WO2001010465A1/de active IP Right Grant
- 2000-07-25 MX MXPA02001254A patent/MXPA02001254A/es active IP Right Grant
- 2000-07-25 ES ES00947994T patent/ES2223549T3/es not_active Expired - Lifetime
- 2000-07-25 PL PL353405A patent/PL198132B1/pl unknown
- 2000-07-25 BR BRPI0013010A patent/BRPI0013010B8/pt not_active IP Right Cessation
- 2000-07-25 EP EP00947994A patent/EP1206281B1/de not_active Expired - Lifetime
- 2000-07-25 CA CA002378424A patent/CA2378424C/en not_active Expired - Lifetime
- 2000-07-25 UA UA2002031831A patent/UA72268C2/uk unknown
- 2000-07-25 CN CNB008114277A patent/CN1246039C/zh not_active Ceased
- 2000-07-25 DK DK00947994T patent/DK1206281T3/da active
- 2000-07-25 RU RU2002106399/15A patent/RU2260429C9/ru active
- 2000-07-25 SI SI200030479T patent/SI1206281T1/xx unknown
- 2000-07-25 KR KR1020027001575A patent/KR100735788B1/ko active IP Right Review Request
- 2000-07-25 AT AT00947994T patent/ATE270104T1/de active
- 2000-07-25 NZ NZ516969A patent/NZ516969A/en not_active IP Right Cessation
- 2000-07-25 IL IL14755300A patent/IL147553A0/xx active IP Right Grant
- 2000-07-25 HU HU0203619A patent/HU229571B1/hu unknown
- 2000-07-25 US US10/049,095 patent/US6548079B1/en not_active Expired - Lifetime
- 2000-07-25 PT PT00947994T patent/PT1206281E/pt unknown
- 2000-07-25 JP JP2001514981A patent/JP5522877B2/ja not_active Expired - Lifetime
- 2000-07-25 AU AU61596/00A patent/AU771058B2/en not_active Expired
- 2000-07-25 CZ CZ20020458A patent/CZ298768B6/cs not_active IP Right Cessation
- 2000-07-25 SK SK168-2002A patent/SK285650B6/sk not_active IP Right Cessation
- 2000-07-31 AR ARP000103958A patent/AR025001A1/es not_active Application Discontinuation
- 2000-08-01 GT GT200000123A patent/GT200000123A/es unknown
- 2000-08-01 TW TW089115369A patent/TWI238719B/zh not_active IP Right Cessation
- 2000-08-02 CO CO00058178A patent/CO5190677A1/es not_active Application Discontinuation
- 2000-08-03 UY UY26269A patent/UY26269A1/es not_active IP Right Cessation
- 2000-08-04 MY MYPI20003581 patent/MY125356A/en unknown
- 2000-08-04 PE PE2000000778A patent/PE20010400A1/es not_active IP Right Cessation
-
2002
- 2002-01-10 IL IL147553A patent/IL147553A/en unknown
- 2002-01-10 ZA ZA200200215A patent/ZA200200215B/en unknown
- 2002-01-30 CU CU20020028A patent/CU23367A3/es unknown
- 2002-01-30 BG BG106366A patent/BG65304B1/bg unknown
- 2002-02-01 NO NO20020526A patent/NO320743B1/no not_active IP Right Cessation
- 2002-02-05 MA MA26508A patent/MA25427A1/fr unknown
- 2002-03-04 HR HR20020198A patent/HRP20020198B1/xx not_active IP Right Cessation
-
2003
- 2003-03-06 HK HK03101660.4A patent/HK1049615B/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU229571B1 (en) | Aqueous compositions containing moxifloxacin and common salt and process for its preparation | |
| KR100451269B1 (ko) | 경구투여용약제학적제산제조성물 | |
| NO336427B1 (no) | Farmasøytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmåte og anvendelse derav | |
| CN101081301A (zh) | 含有培美曲塞的药物组合物 | |
| JP7254101B2 (ja) | 複数回使用のトラセミド組成物 | |
| WO2010090765A2 (en) | Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products | |
| EP0345926B1 (en) | Pharmaceutical compositions containing pentamidine | |
| US11324692B2 (en) | Method to prepare pharmaceutical compositions of suggamadex | |
| CA2179147A1 (en) | Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent | |
| JP2008094743A (ja) | 摂食・嚥下改善食品 | |
| US5064857A (en) | Liquid bismuth containing medicinal product, process for producing it and its use | |
| CN108853476A (zh) | 一种蛋白琥珀酸铁口服溶液及其制备方法 | |
| RU2033164C1 (ru) | Антимикробный лечебный препарат | |
| JP5823131B2 (ja) | 防風通聖散含有組成物 | |
| JP5019923B2 (ja) | プラノプロフェン含有医薬組成物 | |
| JP2019206492A (ja) | 外用組成物 | |
| JP2842689B2 (ja) | 水溶性イボパミン酸付加塩を含有する眼薬 | |
| CN111511222B (zh) | 用于钙补充的组合物 | |
| KR101458670B1 (ko) | 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법 | |
| EP1075257A1 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
| CN107898809A (zh) | 一种葡萄糖酸钙锌口服溶液及其制备方法 | |
| KR101842041B1 (ko) | 하제 조성물 | |
| JP4195218B2 (ja) | 弱アルカリで安定化される薬剤を含む医薬用液剤 | |
| JPH11180864A (ja) | クエン酸アルカリ塩を含有するゼリ−製剤 | |
| JPS633850B2 (pt) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE |
|
| GB9A | Succession in title |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE; BAYER PHARMA AKTIENGESELLSCHAFT, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |
|
| HC9A | Change of name, address |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE; BAYER PHARMA AKTIENGESELLSCHAFT, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |